A Feasibility Randomized Trial Evaluating Early vs Late Stent Removal Following Radical Cystectomy and Ileal Conduit Formation for Bladder Cancer
A legfontosabb adatok
- Hol
- London (Kanada)A helyszín megnézése
AI-kivonat: kiket keres a vizsgálat
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
A vizsgálat olyan felnőtteket keres, akiknek hólyagrák miatt eltávolítják a hólyagját, és ileum conduitot (bélszakaszból készült vizeletelvezetést) alakítanak ki. Azt hasonlítja össze, hogy a ureter-sztenteket korán vagy későn távolítják el.
- Életkor
- 18 éves vagy idősebb
- Nem
- Mindkét nem részt vehet.
- A betegség stádiuma
- Hólyagrák, amelyet radikális cisztektómiával (hólyageltávolítással) és ileum conduit kialakításával kezelnek.
- Korábbi kezelés
- Aki korábban hasi vagy kismedencei sugárkezelést kapott, nem vehet részt.
A részvétel fő kizáró okai
- Olyan kezelés, amely nem a betegség teljes megszüntetését célozza (cT4b, mentő vagy tüneti hólyageltávolítás)
- Más vizeletelvezetési módok (kontinens bőrön át történő elvezetés vagy ortotopikus neoblaszt)
- Korábbi hasi vagy kismedencei sugárkezelés
- Egyidejű felső húgyúti daganat
Gépi kiolvasás: 2026. november 9.
Helyszínek itt: Kanada
- Victoria HospitalLondon, KanadaRésztvevőt keres
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
A vizsgálat adatai
- Ki végzi
- Western University, Canada
- Azonosító
- NCT06595446
- A regiszteradat frissítve
- 2025. április 4.
- Eredeti leírás
Bladder cancer is the 4th most common cancer in men and 5th most common type of cancer in Canada. Urothelial cancer accounts for approximately 90% of malignancies. At diagnosis, over 75% of cases are classified as non-muscle invasive (NMIBC), and with appropriate treatment, the majority of these patients achieve positive outcomes. The progression rate of NMIBC to Muscle-invasive bladder cancer (MIBC) varies between 5-50% at 5 years dependent on histopathological features such as grade, stage, presence of CIS and age (Carcinoma in Situ). The optimal treatment of MIBC (T2-T4N0M0) consists of neoadjuvant cisplatin-based chemotherapy followed by Radical cystectomy and urinary diversion (RCUD). In the last couple of decades, RCUD has also gained attention for treating patients with high-risk non-muscle invasive bladder cancer. Despite advancements in surgical techniques and the rise of minimally invasive alternatives, complications after surgery remain frequent, with morbidity rates of approximately 50%.A teljes eredeti leírásKevesebb
A Feasibility Randomized Controlled Trial Evaluating Early vs Late Stent Removal Following Radical Cystectomy and Ileal Conduit Formation for Bladder Cancer
Bladder cancer is the 4th most common cancer in men and 5th most common type of cancer in Canada. Urothelial cancer accounts for approximately 90% of malignancies. At diagnosis, over 75% of cases are classified as non-muscle invasive (NMIBC), and with appropriate treatment, the majority of these patients achieve positive outcomes. The progression rate of NMIBC to Muscle-invasive bladder cancer (MIBC) varies between 5-50% at 5 years dependent on histopathological features such as grade, stage, presence of CIS and age (Carcinoma in Situ). The optimal treatment of MIBC (T2-T4N0M0) consists of neoadjuvant cisplatin-based chemotherapy followed by Radical cystectomy and urinary diversion (RCUD). In the last couple of decades, RCUD has also gained attention for treating patients with high-risk non-muscle invasive bladder cancer. Despite advancements in surgical techniques and the rise of minimally invasive alternatives, complications after surgery remain frequent, with morbidity rates of approximately 50%.
Several uncertainties persist in surgical practice, including the role of perioperative ureteric stenting during RCUD. Perioperative ureteric stenting is intended to minimize urinary leakage from the newly created uretero-enteric anastomosis and to prevent early obstruction caused by anastomotic swelling. However, stenting may increase the risk of urinary tract infections (UTIs) and necessitate additional follow-up for stent removal. Peng et al. conducted the most recent systematic review in 2021, demonstrating that ureteral stents in RCUD were linked to higher rates of anastomotic strictures. Their review did not provide evidence that these stents were more effective than not using stents in preventing post-diversion urinary leakage. The review underscored the scarcity of prospective randomized controlled trials examining the safety and effectiveness of stenting in this context. The sole prospective (non-randomized) study assessing stent dwell / retention time after RCUD demonstrated early stent removal (2 weeks) had decreased 90-day readmissions and UTIs.
Therefore, the investigators aimed to determine the feasibility of conducting a definitive randomized trial to evaluate patients undergoing radical cystectomy and ileal conduit formation to receive either early stent removal (5-7 days) or late stent removal (4-6 weeks).
Bevonási feltételek: Adult patients (18 years or older) undergoing radical cystectomy and ileal conduit formation for bladder cancer; Able to give informed written consent to participate.
Kizáró feltételek: Patients previously received abdominal/pelvic radiotherapy; Patients with concomitant upper urinary tract cancer; Treatment without curative intent (cT4b, salvage or palliative cystectomies); Patients undergoing alternative forms of urinary diversion (e.g. continent cutaneous urinary diversion or orthotopic neobladder formation).